EE9800131A - Medetomidiini derivaatide levoenantiomeeride farmatseutilised kompositsioonid ja nende kasutamine - Google Patents

Medetomidiini derivaatide levoenantiomeeride farmatseutilised kompositsioonid ja nende kasutamine

Info

Publication number
EE9800131A
EE9800131A EE9800131A EE9800131A EE9800131A EE 9800131 A EE9800131 A EE 9800131A EE 9800131 A EE9800131 A EE 9800131A EE 9800131 A EE9800131 A EE 9800131A EE 9800131 A EE9800131 A EE 9800131A
Authority
EE
Estonia
Prior art keywords
pct
receptors
adrenergic alpha
medetomidine
date
Prior art date
Application number
EE9800131A
Other languages
English (en)
Inventor
E. O. Kerman Karl
Jansson Christian
Kukkonen Jyrki
Savola Juha-Matti
Wurster Siegfried
Cockcroft Victor
Original Assignee
E. O. Kerman Karl
Jansson Christian
Kukkonen Jyrki
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E. O. Kerman Karl, Jansson Christian, Kukkonen Jyrki, Orion Corporation filed Critical E. O. Kerman Karl
Publication of EE9800131A publication Critical patent/EE9800131A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Resins (AREA)
  • Saccharide Compounds (AREA)
EE9800131A 1995-10-23 1996-10-23 Medetomidiini derivaatide levoenantiomeeride farmatseutilised kompositsioonid ja nende kasutamine EE9800131A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521680.0A GB9521680D0 (en) 1995-10-23 1995-10-23 New use of imidazole derivatives
PCT/FI1996/000560 WO1997015302A1 (en) 1995-10-23 1996-10-23 Pharmaceutical compositions of levo-enantiomers of medetomidine derivatives and their use

Publications (1)

Publication Number Publication Date
EE9800131A true EE9800131A (et) 1998-10-15

Family

ID=10782758

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800131A EE9800131A (et) 1995-10-23 1996-10-23 Medetomidiini derivaatide levoenantiomeeride farmatseutilised kompositsioonid ja nende kasutamine

Country Status (22)

Country Link
US (1) US5994384A (et)
EP (1) EP0858338B1 (et)
JP (1) JP2000503298A (et)
KR (1) KR19990067008A (et)
CN (1) CN1200035A (et)
AT (1) ATE218340T1 (et)
AU (1) AU707728B2 (et)
BG (1) BG102396A (et)
CA (1) CA2232336A1 (et)
CZ (1) CZ120498A3 (et)
DE (1) DE69621633T2 (et)
EE (1) EE9800131A (et)
ES (1) ES2178717T3 (et)
GB (1) GB9521680D0 (et)
HU (1) HUP9900027A3 (et)
IL (1) IL123999A (et)
NO (1) NO981799L (et)
NZ (1) NZ320289A (et)
PL (1) PL326562A1 (et)
RU (1) RU2193404C2 (et)
SK (1) SK48698A3 (et)
WO (1) WO1997015302A1 (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
WO2000076502A1 (en) * 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
US6444681B1 (en) 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP1981880B1 (en) 2006-01-27 2010-02-24 F.Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
US9095576B2 (en) 2011-11-21 2015-08-04 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
WO2015011177A1 (en) * 2013-07-24 2015-01-29 I-Tech Ab Use of the enantiomer levomedetomidine as inhibitor for marine biofouling of surfaces
TWI629066B (zh) 2013-10-07 2018-07-11 帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物
TWI624278B (zh) * 2013-10-07 2018-05-21 帝國製藥美國股份有限公司 使用非鎮靜性右美托咪啶經皮組成物用於治療戒斷症候群的方法及組成物
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
RU2018105761A (ru) 2013-10-07 2019-02-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
CN106442765A (zh) * 2016-08-31 2017-02-22 辰欣药业股份有限公司 一种盐酸右美托咪定粗品中异构体的检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
WO1992004054A1 (en) * 1990-08-30 1992-03-19 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY, PORTLAND, OREGON, and THE UNIVERSITY OF OREGON, EUGENE, OREGON, Johnson Hall, University of Oregon Substituted amidines having high binding to the sigma receptor and the use thereof
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB9310965D0 (en) * 1993-05-27 1993-07-14 Ucb Sa 2-hydroxy-3-(1h-imidazol-4-yl)alkyl)benzenecarboximidamides

Also Published As

Publication number Publication date
PL326562A1 (en) 1998-09-28
AU707728B2 (en) 1999-07-15
IL123999A (en) 2002-09-12
WO1997015302A1 (en) 1997-05-01
CN1200035A (zh) 1998-11-25
RU2193404C2 (ru) 2002-11-27
AU7301996A (en) 1997-05-15
CA2232336A1 (en) 1997-05-01
GB9521680D0 (en) 1996-01-03
DE69621633D1 (de) 2002-07-11
KR19990067008A (ko) 1999-08-16
NO981799D0 (no) 1998-04-22
HUP9900027A2 (hu) 1999-04-28
DE69621633T2 (de) 2003-02-06
JP2000503298A (ja) 2000-03-21
SK48698A3 (en) 1999-03-12
BG102396A (en) 1999-01-29
ES2178717T3 (es) 2003-01-01
NZ320289A (en) 1999-08-30
EP0858338B1 (en) 2002-06-05
NO981799L (no) 1998-04-22
US5994384A (en) 1999-11-30
EP0858338A1 (en) 1998-08-19
ATE218340T1 (de) 2002-06-15
HUP9900027A3 (en) 1999-11-29
CZ120498A3 (cs) 1998-09-16

Similar Documents

Publication Publication Date Title
EE9800131A (et) Medetomidiini derivaatide levoenantiomeeride farmatseutilised kompositsioonid ja nende kasutamine
AU2002234134A1 (en) 3-substituted oxindole beta 3 agonists
BR9806801A (pt) Utilização de um antagonista de receptores cb1, composição farmacêutica, e, estojo para o tratamento de distúrbios da apetência
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
AU2506197A (en) Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity
ES2121193T3 (es) Derivados de bencimidazoles.
EP1203586A3 (en) Compositions comprising a mast cell degranulation-blocking agent for treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin.
PT1059915E (pt) Amido de ligacaocruzada com alto teor em amilose tendo grupos funcionais como matriz para a libertacao lenta de agentes farmaceuticos
TR200201795T2 (tr) Proton pompası önleyicileri veya H2 reseptör antagoistleri ile kombinasyon halinde (+) norcisaprid kullanılan metodlar ve terkipler
EP0934069A4 (en) THERAPY OF LIPID AND GLUCOSE METABOLISM DISORDERS AND COMPOSITION THEREOF
DE69633943D1 (de) Morphine derivate mit analgetischen eigenschaften
Jones et al. Characterization of a prostanoid EP3‐receptor in guinea‐pig aorta: partial agonist action of the non‐prostanoid ONO‐AP‐324
AU7213196A (en) Method of treating the navicular disease in horses
ZA954643B (en) Endoparasiticides
ATE197453T1 (de) Imidazol-, triazol- und tetrazolderivate
Balfour et al. Effects of acute D-CPPene on mesoaccumbens dopamine responses to nicotine in the rat
DK0804152T3 (da) Lactulose-pastiller
AU3267097A (en) Methanesulphonate salt of an arylpiperazine derived from tryptamine and its solvates for pharmaceutical use
EP1051994A3 (en) 5HT1 receptor agonists and a COX-2 inhibitor for the treatment of migraine
Trapp et al. Direct interaction of Na‐azide with the KATP channel
Altenburg et al. Tizanidine Protects Mice against Convulsions Induced by Lidocaine: Involvement of α2‐Adrenoceptors
Kitamura et al. Effects of nifedipine and Bay K 8644 on contractile activities in single skeletal muscle fibers of the frog
CA2236269A1 (en) Selective .beta.3 adrenergic agonists
DE69400908D1 (de) Verwendung von riluzol zum schutz gegen strahlenschäden